

CHAPTER ONE: INTRODUCTION.....	1
STUDY OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	2
SCOPE OF THE STUDY.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ABOUT THE AUTHOR.....	3
RELATED BCC RESEARCH REPORTS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	4
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 5
EXECUTIVE SUMMARY.....	5
<i>SUMMARY TABLE WORLDWIDE REVENUE OF ANTIEMETICS, THROUGH 2015 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE WORLDWIDE REVENUE OF ANTIEMETICS, 2008-2015 (\$ MILLION)</i>	6
 CHAPTER THREE: OVERVIEW.....	 7
STAGES IN NAUSEA AND VOMITING.....	7
TYPES OF EMESIS.....	8
RELATIONSHIP BETWEEN RECEPTORS AND NAUSEA.....	8
THE GI TRACT.....	9
THE CHEMORECEPTOR TRIGGER ZONE (CTZ).....	9
THE VESTIBULAR APPARATUS.....	9
THE CEREBRAL CORTEX.....	10
HISTORY.....	10
HISTORY OF PATHOPHYSIOLOGY.....	10
HISTORY OF ANTIEMETIC THERAPY.....	10
<i>TABLE 1 HISTORY OF ANTIEMETIC THERAPY</i>	10
<i>TABLE 1 (CONTINUED)</i>	11
<i>TABLE 2 HISTORY OF SEROTONIN AND 5-HT RECEPTORS</i>	11
<i>TABLE 3 HISTORY OF TACHYKININS AND NEUROKININ RECEPTORS</i>	12
<i>TABLE 4 HISTORY OF CORTICOSTEROIDS</i>	12
<i>TABLE 5 HISTORY OF DOPAMINE AND DOPAMINE RECEPTORS</i>	12
CAUSES OF EMESIS AND ITS THERAPY.....	13
VESTIBULAR INVOLVEMENT.....	13
OBSTRUCTION.....	14
MIND.....	14
INFECTION, IRRITATION, AND INFLAMMATION.....	15
TOXINS.....	15
<i>TABLE 6 CAUSES OF EMESIS AND THE THERAPY INVOLVED</i>	16

CHAPTER FOUR: TYPE OF ANTIEMETIC DRUGS.....	17
TYPES OF ANTIEMETIC DRUGS.....	17
5-HT ₃ RECEPTOR ANTAGONISTS.....	17
<i>TABLE 7 5-HT₃ RECEPTOR ANTAGONISTS DRUG PRODUCTS AS ANTIEMETICS</i>	18
NK ₁ RECEPTOR ANTAGONISTS.....	18
<i>TABLE 8 5NK₁ RECEPTOR ANTAGONISTS DRUG PRODUCTS AS ANTIEMETICS</i>	19
ANTI-HISTAMINES (H ₁ ANTIHISTAMINE RECEPTOR ANTAGONISTS):.....	19
<i>TABLE 9 ANTIHISTAMINES DRUG PRODUCTS AS ANTIEMETICS</i>	19
<i>TABLE 9 (CONTINUED)</i>	20
DOPAMINE ANTAGONISTS.....	20
<i>TABLE 10 DOPAMINE ANATAGONISTS, DRUG PRODUCTS AS ANTIEMETICS</i>	21
STEROID-CORTICOSTEROIDS.....	21
<i>TABLE 11 STEROIDS-CORTICOSTEROIDS, DRUG PRODUCTS AS ANTIEMETICS</i>	22
CANNABINOIDS.....	22
<i>TABLE 12 CANNABINOIDS, DRUG PRODUCTS AS ANTIEMETICS</i>	23
BENZODIAZEPINES.....	23
<i>TABLE 13 BENZODIAZEPINES, DRUG PRODUCTS AS ANTIEMETICS</i>	24
ANTICHOLINERGICS.....	25
<i>TABLE 14 ANTICHOENERGIC DRUG PRODUCTS AS ANTIEMETICS</i>	25
OTHERS.....	25
<i>TABLE 15 OTHER PRODUCTS AS ANTIEMETICS</i>	26
<i>TABLE 16 NON-PHARMACEUTICAL THERAPIES</i>	26
<i>TABLE 16 (CONTINUED)</i>	27
 CHAPTER FIVE: REGULATORY ASPECTS.....	 28
<i>TABLE 17 APPROVALS OF ANTIEMETICS, 2007 TO APRIL 2010</i>	28
<i>TABLE 17 (CONTINUED)</i>	29
<i>TABLE 17 (CONTINUED)</i>	30
<i>TABLE 17 (CONTINUED)</i>	31
<i>TABLE 17 (CONTINUED)</i>	32
<i>TABLE 17 (CONTINUED)</i>	33
<i>TABLE 18 REGULATORY CHANGES OF ANTIEMETICS, 2007 TO APRIL 2010, BY ACTIVE INGREDIENT</i>	34
<i>TABLE 18 (CONTINUED)</i>	35
<i>TABLE 18 (CONTINUED)</i>	36
<i>TABLE 19 SAFETY ALERTS FOR ANTIEMETICS, 2007 TO APRIL 2010, BY ACTIVE INGREDIENT</i>	36
<i>TABLE 19 (CONTINUED)</i>	37

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS	37
REGULATORY UPDATES: APPROVAL, ... (CONTINUED)	38
CHAPTER SIX: INDUSTRY STRUCTURE.....	39
MANUFACTURERS/PRODUCTS FOR ANTIEMETICS.....	39
TABLE 20 LEADING MANUFACTURERS OF 5-HT ₃ RECEPTOR ANTAGONISTS.....	39
TABLE 20 (CONTINUED).....	40
TABLE 21 LEADING MANUFACTURERS OF NK-1 RECEPTOR ANTAGONISTS.....	40
TABLE 22 LEADING MANUFACTURERS OF H ₁ RECEPTOR ANTAGONISTS.....	40
TABLE 22 (CONTINUED).....	41
TABLE 23 LEADING MANUFACTURERS OF DOPAMINE ANTAGONISTS.....	41
TABLE 23 (CONTINUED).....	42
TABLE 24 LEADING MANUFACTURERS/ SUPPLIERS OF STEROIDS-CORTICOSTEROIDS	42
TABLE 25 LEADING MANUFACTURERS/ SUPPLIERS OF CANNABINOIDS.....	43
TABLE 26 LEADING MANUFACTURERS/ SUPPLIERS OF BENZODIAZEPINES.....	43
TABLE 27 LEADING MANUFACTURERS/ SUPPLIERS OF ANTICHOLINERGICS.....	43
MARKET SHARES OF INDUSTRY LEADERS	44
5-HT ₃ RECEPTOR ANATAGONISTS.....	44
TABLE 28 WORLDWIDE MARKET SHARES OF 5-HT ₃ RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%)	44
FIGURE 1 WORLDWIDE MARKET SHARES OF 5-HT ₃ RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%)	45
NK-1 RECEPTOR ANATAGONISTS.....	45
TABLE 29 WORLDWIDE MARKET SHARES OF NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%)	45
H ₁ RECEPTOR ANATAGONISTS	46
TABLE 30 WORLDWIDE MARKET SHARES OF H ₁ RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%)	46
FIGURE 2 WORLDWIDE MARKET SHARES OF H ₁ RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%)	47
DOPAMINE ANATAGONISTS.....	47
TABLE 31 WORLDWIDE MARKET SHARES OF DOPAMINE ANTAGONISTS USED AS ANTIEMETICS, 2009 (%)	47
FIGURE 3 WORLDWIDE MARKET SHARES OF DOPAMINE ANTAGONISTS USED AS ANTIEMETICS, 2009 (%)	48
STEROIDS-CORTICOSTEROIDS	48

<i>TABLE 32 WORLDWIDE MARKET SHARES OF STEROIDS- CORTICOSTEROIDS USED AS ANTIEMETICS, 2009 (%)</i>	48
<i>FIGURE 4 WORLDWIDE MARKET SHARES OF STEROIDS- CORTICOSTEROIDS USED AS ANTIEMETICS, 2009 (%)</i>	49
CANNABINOIDS	49
<i>TABLE 33 WORLDWIDE MARKET SHARES OF CANNABINOIDS USED AS ANTIEMETICS, 2009 (%)</i>	49
<i>FIGURE 5 WORLDWIDE MARKET SHARES OF CANNABINOIDS USED AS ANTIEMETICS, 2009 (%)</i>	50
BENZODIAZEPINES	50
<i>TABLE 34 WORLDWIDE MARKET SHARES OF BENZODIAZEPINES USED AS ANTIEMETICS, 2009 (%)</i>	50
<i>FIGURE 6 WORLDWIDE MARKET SHARES OF BENZODIAZEPINES USED AS ANTIEMETICS, 2009 (%)</i>	51
ANTICHOLINERGICS	51
<i>TABLE 35 WORLDWIDE MARKET SHARES OF ANTICHOLINERGICS USED AS ANTIEMETICS, 2009 (%)</i>	51
<i>FIGURE 7 WORLDWIDE MARKET SHARES OF ANTICHOLINERGICS USED AS ANTIEMETICS, 2009 (%)</i>	52
CHAPTER SEVEN: NEW DEVELOPMENTS.....	53
NEW DEVELOPMENTS.....	53
<i>TABLE 36 WORLDWIDE NEW DEVELOPED DRUGS SINCE 2003</i>	54
<i>TABLE 37 PIPELINE ANTIEMETICS</i>	55
<i>TABLE 37 (CONTINUED)</i>	56
RECENT UPDATES FROM THE ANTIEMETIC WORLD.....	56
RECENT UPDATES FROM THE ... (CONTIUED).....	57
RECENT UPDATES FROM THE ... (CONTIUED).....	58
CHAPTER EIGHT: MARKET ANALYSIS.....	59
5-HT ₃ RECEPTOR ANTAGONISTS	59
MARKET OVERVIEW	60
Market Overview (Continued)	61
MARKET REVENUE.....	62
<i>TABLE 38 WORLDWIDE MARKET FOR 5-HT₃ RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	62
<i>FIGURE 8 WORLDWIDE MARKET FOR 5-HT₃ RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	63
NK1 RECEPTOR ANTAGONISTS	63
MARKET OVERVIEW	64
MARKET REVENUE.....	64

<i>TABLE 39 WORLDWIDE MARKET FOR NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	65
<i>FIGURE 9 WORLDWIDE MARKET FOR NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	65
H1 RECEPTOR ANTAGONISTS.....	66
MARKET OVERVIEW.....	66
MARKET REVENUE.....	67
<i>TABLE 40 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	67
<i>FIGURE 10 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	67
DOPAMINE ANTAGONISTS.....	68
MARKET OVERVIEW.....	68
MARKET REVENUE.....	69
<i>TABLE 41 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	69
<i>FIGURE 11 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	70
STEROIDS -CORTICOSTEROIDS.....	70
MARKET OVERVIEW.....	70
MARKET REVENUE.....	71
<i>TABLE 42 WORLDWIDE MARKET FOR STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	72
<i>FIGURE 12 WORLDWIDE MARKET FOR STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	72
CANNABINOIDS.....	72
MARKET OVERVIEW.....	73
MARKET REVENUE.....	73
<i>TABLE 43 WORLDWIDE MARKET FOR CANNABINOIDS USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	74
<i>FIGURE 13 WORLDWIDE MARKET FOR CANNABINOIDS USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	74
BENZODIAZEPINES.....	74
MARKET OVERVIEW.....	75
MARKET REVENUE.....	75
<i>TABLE 44 WORLDWIDE MARKET FOR BENZODIAZEPINES USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	76

<i>FIGURE 14 WORLDWIDE MARKET FOR BENZODIAZEPINES USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	76
ANTICHOLINERGICS.....	76
MARKET OVERVIEW.....	77
MARKET REVENUE.....	77
<i>TABLE 45 WORLDWIDE MARKET FOR ANTICHOLINERGICS USED AS ANTIEMETICS BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	77
<i>FIGURE 15 WORLDWIDE MARKET FOR ANTICHOLINERGIC USED AS ANTIEMETICS BY REGION, 2008-2015 (\$ MILLIONS)</i>	78
MARKET SHARES.....	78
<i>TABLE 46 WORLDWIDE ANTIEMETICS AGENTS MARKET SHARES BY REGION, 2009 (%)</i>	78
<i>FIGURE 16 WORLDWIDE ANTIEMETICS AGENTS MARKET SHARES BY REGION, 2009 (%)</i>	79
CHAPTER NINE: MARKET BY APPLICATIONS.....	80
MARKET SHARE OF APPLICATIONS.....	80
<i>TABLE 47 WORLDWIDE ANTIEMETIC MARKET SHARES, BY APPLICATION, 2009 (%)</i>	81
<i>FIGURE 17 WORLDWIDE ANTIEMETICS MARKET SHARES, BY APPLICATION, 2009 (%)</i>	81
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV).....	81
CHEMOTHERAPY-INDUCED NAUSEA ...(CONTINUED).....	82
<i>TABLE 48 ANTIMETIC THERAPIES FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING</i>	83
MARKET REVENUE.....	83
<i>TABLE 49 GLOBAL SALES OF ANTIEMETIC DRUGS IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, THROUGH 2015 (\$ MILLIONS)</i>	84
<i>FIGURE 18 GLOBAL SALES OF ANTIEMETIC DRUGS IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2008-2015 (\$ MILLIONS)</i>	84
NAUSEA AND VOMITING DUE TO MOTION SICKNESS.....	85
<i>TABLE 50 ANTIEMETIC THERAPIES FOR NAUSEA AND VOMITING DUE TO MOTION SICKNESS</i>	85
MARKET REVENUE.....	86
<i>TABLE 51 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN MOTION SICKNESS, THROUGH 2015 (\$ MILLIONS)</i>	86
<i>FIGURE 19 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN MOTION SICKNESS, 2008-2015 (\$ MILLIONS)</i>	86
POSTOPERATIVE NAUSEA AND VOMITING.....	87
<i>TABLE 52 ANTIEMETIC THERAPIES FOR POSTOPERATIVE NAUSEA AND VOMITING</i>	87
MARKET REVENUE.....	87

<i>TABLE 53 GLOBAL SALES OF ANTIEMETIC DRUGS IN POSTOPERATIVE NAUSEA AND VOMITING, THROUGH 2015 (\$ MILLIONS)</i>	88
<i>FIGURE 20 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN POSTOPERATIVE NAUSEA AND VOMITING, THROUGH 2015 (\$ MILLIONS)</i>	88
POST-RADIATION NAUSEA AND VOMITING	88
<i>TABLE 54 ANTIEMETIC THERAPIES FOR RADIOTHERAPY INDUCED NAUSEA AND VOMITING</i>	89
MARKET REVENUE.....	90
<i>TABLE 55 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN RADIOTHERAPY-INDUCED NAUSEA AND VOMITING, THROUGH 2015 (\$ MILLIONS)</i>	90
<i>FIGURE 21 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN RADIOTHERAPY INDUCED NAUSEA AND VOMITING, 2008-2015 (\$ MILLIONS)</i>	91
ACUTE GASTROENTERITIS	91
<i>TABLE 56 ANTIEMETIC THERAPIES FOR ACUTE GASTROENTRITIES VOMITING</i>	92
MARKET REVENUE.....	92
<i>TABLE 57 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN ACUTE GASTROENTRITIS, THROUGH 2015 (\$ MILLIONS)</i>	92
<i>FIGURE 22 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN ACUTE GASTROENTRITIS, 2008-2015 (\$ MILLIONS)</i>	93
OTHER CONDITIONS	93
<i>TABLE 58 ANTIEMETIC THERAPIES FOR OTHER CONDITIONS</i>	94
MARKET REVENUE.....	94
<i>TABLE 59 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN OTHER CONDITIONS, THROUGH 2015 (\$ MILLIONS)</i>	94
<i>FIGURE 23 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN OTHER CONDITIONS, THROUGH 2015 (\$ MILLIONS)</i>	95
CHAPTER TEN: PATENT ANALYSIS	96
PATENTS BY YEAR.....	96
<i>TABLE 60 NUMBER OF SIGNIFICANT ANTIEMETIC PATENTS BY YEAR, 2006–2010</i>	97
<i>FIGURE 24 NUMBER OF ANTIEMETIC PATENTS BY YEAR, 2006–2010</i>	97
<i>FIGURE 25 NUMBER OF ANTIEMETIC PATENTS BY YEAR, 2006–2010 (%)</i>	98
PATENTS BY MODE OF ADMINISTRATION	98
<i>TABLE 61 PATENTS BY MODE/ ROUTE OF ADMINISTRATION, 2006–2010</i>	98
<i>FIGURE 26 PATENTS BY MODE/ OUTE OF ADMINISTRATION, 2006–2009</i>	99

PATENTS BY TYPE/CATEGORY	99
<i>TABLE 62 PATENTS BY TYPE/ CATEGORY FOR ANTIEMETICS, 2006–2010</i>	100
<i>FIGURE 27 PATENTS BY TYPE/CATEGORY FOR ANTIEMETICS, 2006–2009</i>	101
PATENTS BY COMPANY.....	101
<i>TABLE 63 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTIEMETICS, 2006–2010</i>	102
<i>FIGURE 28 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTIEMETICS, 2006–2010</i>	102
PATENTS BY COUNTRY	103
<i>TABLE 64 NUMBER OF U.S. PATENTS BY COUNTRY FOR ANTIEMETICS, 2006–2010</i>	103
<i>FIGURE 29 NUMBER OF U.S. PATENTS BY COUNTRY FOR CONTRAST AGENTS, 2006–2010</i>	103
<i>TABLE 65 PATENT SHARES BY COUNTRY FOR ANTIEMETICS, 2006–2010 (%)</i>	104
<i>FIGURE 30 PATENT SHARES BY COUNTRY FOR ANTIEMETICS, 2006–2010 (%)</i>	104
ANTIEMETICS PATENTS WORLDWIDE	104
<i>TABLE 66 NUMBER OF ANTIEMETIC PATENTS ISSUED BY DIFFERENT PATENT ORGANIZATIONS WORLDWIDE, 2006–2010</i>	105
<i>FIGURE 31 ANTIEMETIC PATENTS ISSUED BY DIFFERENT PATENT ORGANIZATIONS WORLDWIDE, 2006–2010</i>	106
PATENTS BY ASSIGNEE (WORLDWIDE).....	106
<i>TABLE 67 PATENTS BY ASSIGNEE (WORLDWIDE) FOR ANTIEMETICS, 2006–2010</i>	106
<i>FIGURE 32 PATENTS BY ASSIGNEE (WORLDWIDE) FOR ANTIEMETICS, 2006–2010</i>	107
 CHAPTER ELEVEN: CURRENT SITUATION OF ANTIEMETICS	
MARKET	108
MARKET RESTRAINTS	108
COMPETITION.....	108
COST OF THE DRUGS	109
PATENTS EXPIRATIONS	109
<i>TABLE 68 PATENT EXPIRATIONS</i>	109
GROWTH FACTORS.....	110
LIFE EXPECTANCY	110
PATENT PROTECTION.....	110
DRUGS PORTFOLIO MANAGEMENT	110
FUTURE OF ANTIEMETICS MARKET.....	110
<i>TABLE 69 COMPARISON OF I AND II GENERATION 5-HT₃ RECEPTOR ANTAGONISTS</i>	111

CHAPTER TWELVE: COMPANY PROFILES	112
ABBOTT LABS	112
ACTAVIS	113
AKORN, INC. AND AKORN STRIDES	113
APOTEX INC.	114
APP PHARMACEUTICALS	114
ASTELLAS PHARMA GMBH	115
AUROBINDO PHARMA	115
BAXTER HEALTHCARE CORPORATION	116
BEDFORD LABORATORIES	117
BIOVAIL PHARMACEUTICALS, INC.	117
CADILA PHARMACEUTICALS LTD.	118
CIPLA LTD.	119
CLARIS LIFESCIENCES	119
CORE PHARMA LLC	120
CYPRESS PHARMACEUTICAL, INC.	120
DR. REDDY'S LABORATORIES LTD.	121
EISAI INC.	122
GLAND PHARMA LTD	122
GLAXO SMITHKLINE	123
GLENMARK GENERICS LIMITED	124
GROUP TECHNICALE-FARMOZ S.A	124
G & W LABS	125
HAMELN PHARMACEUTICALS LTD.	125
HAWTHORN PHARMACEUTICALS, INC.	126
HELSINN HEALTHCARE SA/EISAI	126
HETERO DRUGS LIMITED	127
HIKMA FARMACEUTICA PLC	127
HOSPIRA	128
IMPAX LABS	128
INSIGHT PHARMACEUTICALS CORP.	129
IPCA LABS LTD.	130
JANSSEN (A DIVISION OF ORTHO MCNEIL JANSSEN, J & J)	130
KING PHARMACEUTICALS INC.	131
KVK-TECH, INC.	132
LUITPOLD PHARMACEUTICALS, INC.	132
MANX PHARMA LTD.	133
MEDA PHARMACEUTICALS	134
MERCK & CO., INC.	134
MYLAN	135
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD.	136
NOVELL PHARMACEUTICAL LABORATORIES	136
PAR PHARMACEUTICALS	137
PFIZER INC.	138

PIRAMAL HEALTHCARE LIMITED	138
PLIVA HRVATSKA DOO (TEVA GROUP COMPANY)	139
PROSTRAKAN GROUP PLC	139
ROCHE LABORATORIES (F. HOFFMANN-LA ROCHE AG)	140
ROSEMONT PHARMACEUTICALS LTD.	141
SALIX PHARMACEUTICALS INC.	142
SANOFI AVENTIS US	142
SATO PHARMACEUTICALS	143
SCHWARZ PHARMA (UCB SUBSIDIARY)	144
SOLVAY PHARMACEUTICALS (UNIMED/ABBOTT)	144
STRATIVA PHARMACEUTICALS	145
SUN PHARMACEUTICAL INDUSTRIES LTD.	145
TARO PHARMACEUTICAL INDUSTRIES LTD.	146
TEVA PHARMACEUTICAL INDUSTRIES LTD.	146
TORRENT PHARMACEUTICALS	147
WALLACE PHARMACEUTICALS LTD.	148
WATSON PHARMACEUTICALS, INC.	148
WOCKHARDT USA LLC	149
ZYDUS CADILA	149
ZYDUS PHARMS USA	150
 CHAPTER THIRTEEN: ABBREVIATIONS	 151
<i>TABLE 70 ABBREVIATIONS</i>	151
<i>TABLE 70 (CONTINUED)</i>	152
<i>TABLE 70 (CONTINUED)</i>	153